Skip to main content
SpringerLink
Log in

Cervarix, GlaxoSmithKline's cervical cancer vaccine, has been confirmed as the vaccine the Dutch National Immunisation Programme (NIP) will supply.

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. GlaxoSmithKline.Cervarix, GSK's cervical cancer vaccine, wins tender for Dutch national immunisation programme. Media Release: 20 Nov 2008. Available from: URL: http://www.gsk.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cervarix, GlaxoSmithKline's cervical cancer vaccine, has been confirmed as the vaccine the Dutch National Immunisation Programme (NIP) will supply.. Pharmacoecon. Outcomes News 567, 14 (2008). https://doi.org/10.2165/00151234-200805670-00031

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805670-00031

Keywords

Search

Navigation